Strengthening retinopathy of prematurity screening and treatment services in Nigeria: a case study of activities, challenges and outcomes 2017-2020. by Ademola-Popoola, Dupe S et al.
Ademola- Popoola DS, et al. BMJ Open Ophth 2021;6:e000645. doi:10.1136/bmjophth-2020-000645 1
Original research
Strengthening retinopathy of prematurity 
screening and treatment services in 
Nigeria: a case study of activities, 
challenges and outcomes 2017-2020
Dupe S Ademola- Popoola   ,1,2 Iretiola B Fajolu,3 Clare Gilbert,4 
Bolutife A Olusanya,5 Oluwatoyin H Onakpoya,6 Chinyelu N Ezisi,7 
Kareem O Musa,8 Robison Vernon Paul Chan,9 Valentina W Okeigbemen,10 
Rilwan C Muhammad,11 Aeesha N J Malik,12 Adedayo O Adio,13 
Olubunmi T Bodunde,14 Abdulkadir L Rafindadi,15 Tunji S Oluleye,16 
Olukemi O Tongo,17 Sarat A Badmus,18 Olufunmilayo V Adebara,19 
Tapas Ranjan Padhi   ,20 Beatrice N Ezenwa,3 Tokunbo S Obajolowo,2 
Lateefat B Olokoba,21 Victoria A Olatunji,21 Yewande Olubunmi Babalola,16 
Mary O Ugalahi,5 Adetunji Adenekan,22 Omotayo O Adesiyun,23 Jagdish Sahoo,24 
Marilyn T Miller,25 Odarosa M Uhumwangho,26 Adeduntan S Olagbenro,14 
Ebunoluwa A Adejuyigbe,27 Chinyere V C Ezeaka,3 Olugbenga Mokuolu,28 
Tinuade A Ogunlesi,29 Olusoga B Ogunfowora,29 Isa Abdulkadir,30 
Fatima L Abdullahi,30 Abosede T Fabiyi,31 Laila H L Hassan,30 
Aderonke M Baiyeroju,5 Peace I Opara,32 Kehinde Oladigbolu,15 Augusta U Eneh,32 
Bassey E Fiebai,33 Fatima A Mahmud- Ajeigbe,15 Elijah N Peter,15 
Hawwa S Abdullahi15
To cite: Ademola- Popoola DS, 
Fajolu IB, Gilbert C, et al.  
Strengthening retinopathy 
of prematurity screening 
and treatment services in 
Nigeria: a case study of 
activities, challenges and 
outcomes 2017-2020. 
BMJ Open Ophthalmology 
2021;6:e000645. doi:10.1136/
bmjophth-2020-000645
Received 20 March 2021
Accepted 2 August 2021
For numbered affiliations see 
end of article.
Correspondence to
Dr Dupe S Ademola- Popoola;  
dupsyp@ yahoo. com
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Objectives Retinopathy of prematurity (ROP) will become 
a major cause of blindness in Nigerian children unless 
screening and treatment services expand. This article 
aims to describe the collaborative activities undertaken to 
improve services for ROP between 2017 and 2020 as well 
as the outcome of these activities in Nigeria.
Design Descriptive case study.
Setting Neonatal intensive care units in Nigeria.
Participants Staff providing services for ROP, and 
723 preterm infants screened for ROP who fulfilled 
screening criteria (gestational age <34 weeks or birth 
weight ≤2000 g, or sickness criteria).
Methods and analysis A WhatsApp group was 
initiated for Nigerian ophthalmologists and neonatologists 
in 2018. Members participated in a range of capacity- 
building, national and international collaborative activities 
between 2017 and 2018. A national protocol for ROP 
was developed for Nigeria and adopted in 2018; 1 year 
screening outcome data were collected and analysed. In 
2019, an esurvey was used to collect service data from 
WhatsApp group members for 2017–2018 and to assess 
challenges in service provision.
Results In 2017 only six of the 84 public neonatal 
units in Nigeria provided ROP services; this number had 
increased to 20 by 2018. Of the 723 babies screened in 
10 units over a year, 127 (17.6%) developed any ROP; 
and 29 (22.8%) developed type 1 ROP. Only 13 (44.8%) 
babies were treated, most by intravitreal bevacizumab. 
The screening criteria were revised in 2020. Challenges 
included lack of equipment to regulate oxygen and to 
document and treat ROP, and lack of data systems.
Conclusion ROP screening coverage and quality 
improved after national and international collaborative 
efforts. To scale up and improve services, equipment for 
neonatal care and ROP treatment is urgently needed, as 
well as systems to monitor data. Ongoing advocacy is also 
essential.
INTRODUCTION
Africa and Asia are responsible for over half 
(52%) of live births worldwide and over 
80% of babies born preterm. Worldwide, 9 
of the 11 countries with preterm birth rates 
over 15% are in sub- Saharan Africa (SSA).1 2 
Nigeria has about 7 141 000 births annually, 
approximately 803 000 of which are born 
at less than 37 weeks gestational age (GA), the 
third highest after India and China. About 
43 800 of these babies have a GA of less than 
28 weeks.2
Over the last decade, there have been 
notable improvements in human and tech-
nical resource capacity for health in SSA. In 
particular, the number of trained ophthal-
mologists available to perform retinopathy 
of prematurity (ROP) screening has recently 
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increased, due partly to the subspecialty fellowship 
programme provided by the United Kingdom’s Common-
wealth Eye Health Consortium (CEHC).3 Over the same 
period, the survival of preterm babies has also increased as 
a result of several government and development partner 
initiatives to expand the provision of neonatal intensive 
care units (NICUs). However, in Nigeria, there are no 
national guidelines on oxygen delivery and monitoring, 
or on target saturation levels for preterm infants in these 
units,2 despite World Health Organization (WHO)4 5 
recommendations.
About one- third of neonatal admissions in Nigeria 
are babies born preterm, almost one- third (31%) have 
a GA less than 32 weeks6 7 In 2018, survival rates to 
discharge among preterm infants most at risk of ROP 
in one NICU was 58% for infants with a GA of 26–27 
weeks, and 81% at 28–33 weeks. Likewise, the survival of 
extremely low birth weight babies (BW <1000 g) improved 
from 28% in 2010 to 43% in 2018, and survival was 80% 
for very low birth weight (1000–1499 g) babies in 2018.8 
However, the increasing survival without a corresponding 
increase in ROP screening and treatment services has led 
to reports of infants becoming blind from ROP.9 10 In 
the last quarter of 2016, three children presented with 
blinding ROP to the paediatric ophthalmology clinic in 
Ilorin (DAP, personal communication). The concern 
that an epidemic of ROP blindness was imminent served 
as the drive to strengthen ROP care in Nigeria, as has 
occurred in South Africa, which now has a national ROP 
programme.11
With regards to screening criteria, ‘one size does not 
fit all’ as larger, more mature infants also develop type 1 
ROP in resource- limited settings than in well resourced 
settings.12 Variation in the population of preterm infants 
at risk is reflected in national ROP screening guidelines in 
many low and middle income countries, including South 
Africa (2013)13 and Kenya (2018).14 In these countries 
the screening criteria include a GA of up to 32 weeks, or 
a BW of up to 1501 g; or infants with a GA greater than 
32–35 weeks or BW of 1501–2000 g with comorbidities, at 
the request of the neonatologist.13 14 In India the criteria 
are wider; that is, GA 4 weeks or BW of up to 2000 g.15
In Nigeria, the most populous country in Africa, there 
are 42 federal government tertiary hospitals with large 
NICUs,16 and a similar number of state government 
hospitals also provide neonatal services. In 2016, there 
was no national protocol for ROP screening. At that time, 
the six hospitals providing ROP services used different 
criteria, with GA criteria ranging from less than 32 weeks 
to less than 35 weeks, and BW criteria from less than 
1200 g to less than 1900 g.17–19
This case study describes the processes and collabo-
rative activities undertaken to promote ROP services in 
NICUs in Nigeria following the realisation that ROP is an 
emerging public health problem. The outcomes of these 
efforts are also reported.
METHODS
This was a descriptive case study. After the perceived 
increase in blindness from ROP observed in late 
2016, a number of activities and processes were initi-
ated (figure 1). This included advocacy for screening, 
enhancement of communication and collaboration 
between professional colleagues, capacity building and 
skills transfer, and the development of a national ROP 
screening protocol. In addition, an esurvey was under-
taken to assess the status of essential equipment for 
neonatal care and ROP, and the challenges encountered 
in delivering services in Nigeria. In addition, data from 
the first collaborative ROP screening activity in Nigeria 
using the new protocol were collected and analysed.
Advocacy for ROP screening
Advocacy efforts were started in 2017 by local leaders in 
ROP care by engaging members of the Nigerian Paediatric 
Ophthalmology and Strabismus Society (NIPOSS). Efforts 
were directed towards critical stakeholders, including 
hospital administrators, neonatologists and paediatricians, 
NICU nurses, ophthalmologists, midwives and obstetri-
cians, parents of preterm infants, and the general public 
through short radio jingles. In addition, presentations on 
ROP and its blinding consequences on the child, their 
family and caregivers, including medico- legal implica-
tions, were delivered at three national society meetings of 
ophthalmologists, paediatricians and neonatologists.
Communication and collaboration
A social media (WhatsApp) chat group was formed, 
the ‘Nigeria ROP Team’, to improve communication, 
Key messages
What is already known about this subject?
 ► Retinopathy of prematurity (ROP), a vasoproliferative disease 
of the retina that occurs in preterm and low birth weight babies, 
is becoming more common in Nigeria as a result of better neo-
natal survival rates. Screening and prompt treatment, although 
technology- dependent, are vital for preventing blindness from ROP. 
There are regional variations in screening criteria based on levels of 
socioeconomic development.
What are the new findings?
 ► Leadership, advocacy, networking and collaborative teamwork 
were important for the initiation and enhancement of ROP services. 
Development of a national screening protocol facilitated the detec-
tion, treatment and reporting of sight- threatening ROP in Nigerian 
babies. Major challenges encountered included inadequacy of 
equipment for monitoring oxygen delivery, lack of wide field imag-
ing systems for documentation, and lack of laser equipment.
How might these results change the focus of research or 
clinical practice?
 ► The findings of this study have resulted in a modification of national 
screening criteria and also provide further evidence to strength-
en on- going advocacy to both governmental agencies and non- 
governmental organizations for the provision of equipment and 
facilities for ROP services.
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collaboration, and to share experiences and resources 
among ROP teams on 8 August 2018. Links to join the 
groups were shared with members of NIPOSS, the Vitreo- 
Retinal Society of Nigeria (VRSN) and the Nigeria Society 
for Neonatal Medicine (NISONM).
Capacity building and skills transfer
Capacity- building opportunities were provided by the 
UK’s Queen Elizabeth Diamond Jubilee Trust (The Trust; 
2012–2019) through the Commonwealth Eye Health 
Consortium’s fellowship programme, which included 
a south- south Retinopathy of Prematurity Network 
(ROP- NET).20 Between 2014 and 2019, 18 Nigerian 
ophthalmologists underwent paediatric ophthalmology 
training fellowships in designated training institutions, 
several of which were in India where ROP services are 
expanding. The ROP- NET supported capacity building, 
quality improvement and scale- up of ROP screening 
through a partnership between the University of Ilorin 
Teaching Hospital, Nigeria and centres of excellence in 
India between 2017 and 2019. The ophthalmology part-
nership was with ROP experts in LV Prasad Eye Institute, 
Bhubaneswar, India and with neonatal partners from the 
Institute of Medical Sciences and Sum Hospital in India. 
Activities included joint planning meetings followed by 
reciprocal visits for workshops and hands- on training in 
ROP screening and treatment.
Development of ROP screening protocol
The International Paediatric Ophthalmology and Stra-
bismus Council (IPOSC) ran a workshop on ROP for 
African countries in Cape Town in September 2018. The 
Nigerian participants, including neonatologists, ophthal-
mologists and NICU nurses from five institutions, held a 
face- to- face meeting chaired by one of the authors (DAP), 
a paediatric ophthalmologist and Chair of NIPOSS at the 
time, and reached a consensus on the need for a stan-
dardised, national protocol for ROP for Nigeria. Interim 
screening criteria and timing of the first screening were 
agreed by consensus, and it was agreed that evidence on 
the population at risk of type 1 ROP was needed to refine 
the criteria.
The protocol, which was finalised within a month of 
the meeting by email, was shared with participants from 
35 Nigerian institutions on the WhatsApp group. The 
agreed criteria for screening were: (1) infants with GA 
of up to 34 weeks or BW of less than 2000 g; (2) late 
preterm infants (>34 but <37 weeks) if exposed to risk 
factors (prolonged oxygen supplementation, multiple 
episodes of apnoea, blood transfusion, respiratory distress 
syndrome, intraventricular haemorrhage or sepsis); or at 
the request of NICU staff because of stormy postnatal 
events. The first screening should occur around 28 days 
of life, or earlier if the infant was to be discharged before 
28 days. Screening before discharge in these settings has 
been shown to increase follow- up after discharge.21 This 
initial protocol was presented to relevant authorities in 
the Federal Ministry of Health and was adopted for use 
in the development of the treatment guidelines for child 
eye health services in Nigeria.22 Patient records were 
paper based, and data for this study were extracted and 
entered into a Microsoft Excel spreadsheet. The charac-
teristics of the babies who developed type 1 ROP were 
used to review the screening protocol at a virtual meeting 
in July 2020.
E-survey
In order to assess the status of ROP services in Nigeria, an 
online survey was used to collect information separately 
Figure 1 Activities for retinopathy of prematurity (ROP) in Nigeria 2016–2020. IPOSC, International Pediatric Ophthalmology 
and Strabismus Council.
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for the years 2017 and 2018 on the duration, frequency 
and regularity of ROP screening, participants’ confi-
dence in providing services for ROP, and challenges 
they had encountered in screening and treatment. The 
questionnaire was designed by one of the authors (DAP) 
and sent to a few key members (ophthalmologists and 
neonatologists) of the WhatsApp group for feedback and 
comments. The final questionnaire was created in Google 
forms, where the first question was to obtain consent to 
participate. The survey, which had 10 closed questions 
and one free text question on challenges encountered 
with ROP services, was not advertised and did not 
include consistency checks. All questions were compul-
sory and particpants were not able to change their initial 
responses. All items provided a non- response option 
such as ‘not applicable’ in line with CHERRIES check-
list recommendations.23 A link to the form was sent to all 
members of the Nigeria ROP Teams WhatsApp group. 
In the invitation, members were requested to designate 
one individual (an ophthalmologist or neonatologist) 
per institution to complete the form. The email address 
of this individual was used to log onto the esurvey, which 
allowed participants’ institutions to be identified as well 
as duplicate records. The link was sent on 1 January 2019 
and responses were requested by the end of the month. 
Data were then exported into Excel, and extracted and 
analysed for this paper using frequency distributions.
Patients and the public were not involved in the design, 
conduct, reporting, or dissemination plans of this study.
RESULTS
Outcome of advocacy, communication, capacity building and 
skills transfer
By August 2019 the ‘ROP Team Nigeria’ WhatsApp group 
had 40 participants: 18 ophthalmologists, 12 neonatolo-
gists/paediatricians and 10 NICU nurses.
National and international collaboration meetings for capacity 
building and skills transfer
The number of tertiary level public NICUs in Nigeria 
was 84; in 2017, six were providing ROP services which 
increased to 20 in 2018. Screening was weekly and regular 
in 15 (75%) NICUs, but was but irregular or infrequent 
in five. Three ROP- blind children were seen in 2017 and 
one in 2018 (figure 2). The number of ophthalmologists 
confident in ROP screening increased from 10 to 23 over 
the same period.
ROP screening and treatment
Following development of the protocol, 10 ROP teams 
in tertiary hospitals across Nigeria participated in a 
1 year prospective study of ROP using the protocol, from 
September 2018 to August 2019. A total of 723 infants 
were screened, 475 (65.7%) had GA of less than 32 weeks 
and 71 (9.8%) had a GA of more than 32 weeks, while 
517 (71.5%) had a BW of up to 1500 g. A total of 127 
(17.6%) babies developed any ROP; 29 (4.0%) had type 
1 ROP. The median GA of infants with type 1 ROP was 28 
weeks (IQR 27–29 weeks), and the median BW was 1034.3 
g (IQR 935–1174 g); a comparatively large number of 
babies were examined to diagnose ROP in babies with 
birth weight over 1200 g and beyond 31 weeks (table 1, 
figure 3).
Only one infant developed aggressive posterior ROP 
(APROP). Twenty- seven of the 29 babies with type 1 ROP 
had a GA of less than 32 weeks (27/475, 5.2%) or a BW 
of 1500 g (27/517, 5.6%). The two infants with type 1 
ROP with a GA of at least 32 weeks and a BW of more 
than 1500 g had experienced a stormy neonatal period, 
with Candida sepsis and multiple apnoeic attacks. Other 
risk factors for ROP included anaemia in 19 (65.5%), 
apnoea/respiratory distress syndrome and sepsis, each in 
18 (62.1%) babies.
Only 13 (44.8%) of the 29 infants with type 1 ROP 
were treated: one had primary diode 810 laser treatment, 
and 12 (92.3%) had anti- vascular endothelial growth 
factor (VEGF; bevacizumab) injections because this was 
the only treatment available in 90% of the institutions. 
Two (16.7%) of these 12 infants subsequently had laser 
treatment for persistent disease. In 12 infants, the ROP 
regressed; in one, it progressed to stage 4b. Sixteen 
infants (56.2%) were not treated; 14 parents could not 
afford the treatment, one did not consent, and one infant 
died within 24 hours of the diagnosis.
At a meeting on 21 July 2020, the Nigerian ROP Team 
took a unanimous decision to adjust the BW component 
of the ROP screening criteria, from up to 2000 g to up 
to 1500 g, while maintaining the GA criterion of  up to 
34 weeks. Neonatologists may still request screening for 
more mature or heavier infants if they have been exposed 
to risk factors. It was agreed that these criteria would be 
used for another year, after which they would be reviewed 
again.
Online E-survey findings
Twenty Nigerian institutions offering ROP services 
responded to the online e- survey. Five were not providing 
regular services, and the challenges encountered in the 
15 institutions providing regular services are reported 
(table 2). The main challenge in all the institutions was a 
lack of wide- field imaging systems to document findings 
even though smartphones were used for retinal imaging 
Figure 2 Status of retinopathy of prematurity (ROP) 
programme in Nigeria in 2017 and 2018.
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by two institutions. Lack of equipment to regulate oxygen 
in NICUs was another universal challenge. Two- thirds of 
institutions lacked a laser for ROP treatment.
DISCUSSION
ROP emerged as an increasingly important cause of 
blindness in children in middle- income countries over 
20 years ago.24 More recently this ‘third epidemic of ROP 
blindness’ emerged in South Africa25 and in other low- 
income African countries.26 27 Few studies on ROP were 
published from SSA before the year 2000,19 28 which prob-
ably reflects the very high mortality of preterm infants at 
the time.
In 2017, only six of the 84 NICUs in government- owned 
institutions in Nigeria provided regular ROP screening, 
which had increased to 20 by early 2019. More work needs 
to be done to increase the number of centres screening 
and managing ROP. In terms of human resources, the 
number of ophthalmologists with relevant competen-
cies for ROP screening and management increased 










type 1 ROP %
25 5 0.7 1 3.5 ≤800 53 7.3 3 10.3
26 35 4.8 3 10.3 801–1000 80 11.1 11 37.9
27 35 4.8 5 17.2 1001–1200 119 16.4 11 37.9
28 115 15.9 11 37.9 1201–1400 192 26.6 1 3.5
29 65 9.0 2 6.9 1401–1500 73 10.1 1 3.5
30 75 10.4 2 6.9 >1500 206 28.5 2 6.9
31 145 20.1 3 10.3
32 177 24.5 0 0
33 40 5.5 1 3.5
34 31 4.3 1 3.5
>34 weeks 0 0.0 0 0.0






ROP, retinopathy of prematurity .
Figure 3 Birth weight and gestational ages of babies 
developing type 1 retinopathy of prematurity (ROP).
Table 2 Challenges in the 15 institutions delivering routine 
ROP screening in Nigeria
Challenges Frequency %
Lack of equipment and consumables
  Electronic systems to document 
ROP findings
15 100
  Lack of equipment to regulate 
oxygen in NICUs
15 100
  No laser for treatment 10 66.7




  Data management 13 86.7
  Financial support for treatment 10 66.7
  Late referral 6 40.0
  ROP coordinator/support staff/
inadequate manpower
4 26.7
  Poor motivation and transportation 
issues for parents and team
4 26.7
  Follow- up 4 26.7
NICU, neonatal intensive care unit; ROP, retinopathy of 
prematurity.
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from 10 to 23 over the same period, largely due to the 
capacity- building opportunities provided by the Trust’s 
south- south ROP- NET partnership and the CEHC fellow-
ship programme.
Collaborative efforts between professional societies of 
ophthalmologists and neonatologists in Nigeria as well 
as other non- governmental organisations resulted in the 
development of the first protocol for ROP. This not only 
standardised the provision of services, but as has been 
shown in South American countries, the development 
of guidelines is a mechanism for engaging ministries of 
health, which is key to scaling up services.29 30
The outcome of these activities provides further 
evidence to support the positive impact of leadership, 
collaboration and advocacy in developing, implementing 
and scaling up services for greater coverage and align-
ment of services.29 This was demonstrated by the more 
than three- fold increase in the number of institutions 
providing ROP services in Nigeria over a 3- year period.
In our study, 4.0% of the babies screened in 10 NICUs 
developed type 1 ROP, comparable to reports from other 
SSA countries (1–8.7%).25 26 31 32 The proportion of 
infants with any ROP was lower than reported in other 
studies from Africa, which reflect narrower screening 
criteria used in some of these countries. Most of the 
infants with type 1 ROP had a GA of less than 32 weeks 
or a BW of less than 1500 g, and there were two outliers, 
one with a GA of 34 weeks. These findings supported 
the Nigerian team’s decision to keep the GA screening 
criteria at up to 34 weeks GA and adjust the BW to 1500 g 
or lower, and the inclusion of older or bigger infants with 
stormy clinical course. The finding that approximately 
5% of infants with a GA less than 32 weeks or a BW up to 
1500 g developed type 1 ROP despite the relatively high 
median GA (28 weeks) suggests that more needs to be 
done to improve the quality of neonatal care in Nigeria.
In this study, less than half of the infants with Type 1 
ROP were treated, either due to lack of lasers or parental 
consent, or the high cost of anti- VEGF treatment or infant 
death. This situation needs to be addressed as a matter 
of urgency through advocacy, mobilisation of resources, 
better counselling of parents, and by ensuring that ROP 
management is included in Universal Health Coverage 
financing schemes.
The use of anti- VEGF agents in the management of ROP 
is becoming increasingly popular globally,33–35 including in 
this study where, in the absence of lasers, it was the primary 
treatment in most infants (92.3%). Advantages of anti- VEGF 
treatment over laser include that it is quicker to administer, 
can give early resolution of active disease, and may be asso-
ciated with fewer cases of early- onset high myopia. However, 
the disadvantages are late reactivation of disease, as occurred 
in two infants in this study, which can occur many months 
later in an unpredictable manner. Most importantly, there is 
potential for systemic complications due to the suppression 
of endogenous VEGF while many organs are still developing. 
Determining which is the best anti- VEGF agent for ROP, and 
the indications, timing and dose required, are active areas of 
research.36 For example, a recent dosing study suggests that 
0.004 mg bevacizumab may be the lowest effective dose37; 
that is, 1/150th of the 0.625 mg dose used in the BEAT- ROP 
trial, but evidence from clinical trials is needed before doses 
can be reduced to these levels.
While most centres conducted regular weekly 
screening, five reported infrequent screening (some 
were screening at quarterly intervals). This is concerning 
as babies with type 1 ROP are likely to be missed. Efforts 
to increase neonatologists’ ownership and awareness are 
required. Systems to collect and monitor data on ROP 
services, preferably electronic, are also required so that 
data can be compared between units and tracked over 
time, and to identify the uptake and completeness of 
screening and the outcome of treatment.
Also highlighted is the need for peer support for 
training in screening and treatment with provision of 
equipment. A lack of skilled ophthalmologists is likely to 
remain a considerable constraint to scaling up services 
in the future, particularly for screening using indirect 
ophthalmoscopy. Under these circumstances, telemedi-
cine as used in India38 has much to offer; retinal images 
are captured by highly competent, visiting teams of 
trained technicians, with remote image analysis by an 
ROP expert. Real- time image analysis using artificial 
intelligence to identify infants with plus disease, a key 
sign of type 1 ROP, is also on the horizon,39 with great 
potential for scaling up services.
As in many low- income and middle- income coun-
tries, there were challenges with delivering high- quality 
neonatal care to ensure that sick newborns survive and 
thrive.40 Exposure to hyperoxia and fluctuating hypoxia- 
hyperoxia are well recognised risk factors for ROP. In the 
15 Nigerian institutions included in this study, there was a 
complete lack of air- oxygen blenders and an inadequate 
number of pulse oximeters to monitor oxygen saturation. 
This may explain the relatively high proportion of infants 
with type 1 ROP despite the relatively broad screening 
criteria. Advocacy with the Ministry of Health is required 
to ensure that policies for sick and preterm newborns 
include the safe delivery of oxygen from immediately 
after birth, with target saturations, as recommended 
by WHO.4 Ensuring these policies are in place and are 
implemented is critical as neonatal care services continue 
to expand.
CONCLUSIONS
ROP services in Nigeria have improved over the past 
3 years as a result of local leadership and several national 
and international collaborative efforts. More effort will 
be required to scale up services to other NICUs using 
the revised screening criteria. In particular, there is an 
urgent need to provide wide- field imaging systems for 
screening which can be done by non- ophthalmologists, 
and lasers and anti- VEGF for treatment, with financing 
mechanisms which ensure that no infants are denied 
treatment because parents cannot afford it. To prevent 
ROP, advocacy with the Ministry of Health is required to 
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establish national protocols for safe oxygen delivery in all 
NICUs. Continuous collaboration and ongoing advocacy 
for support from all stakeholders, government, interna-
tional and local NGOs are required to control blindness 
from ROP in Nigeria.
Further research is required using the revised criteria; 
this might help reduce the high number needed to diag-
nose ROP in babies with birth weight over 1200 g and 
beyond 31 weeks, thereby improving efficiency of ROP 
programmes.
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